重要内容提示： 股票简称：海正药业 股票代码：600267 公告编号：临 2023-89 号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总 股本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 应当在事实发生之日起 3 日内予以公告。现将公司回购股份进展情况公告如下： 截至 2023 年 8 月 24 日，公司通过集中竞价交易方式已累计回购股份 12,263,000股，占公司总股本的比例为1.0153%，与上次披露数相比增加0.0948%， 购买的最高价为 11.673 元/股、最低价为 10.13 元/股，已支付的总金额为 128,685,380.67 元（不含交易费用）。 上述回购符合相关法律法规和公司回购股份方案的要求。 三、其他说明 公司后续将按照《上海证券交易所上市公司自律监管指引第 7 号——回购股 份》等规范性文件的要求及市场情况在回购期限内实施回购计划，并根据相关法 律法规和规范性文件的要求及时履行信息披露义务。敬请广 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第九届董事会第十七次 会议于 2023 年 8 月 18 日（周五）下午以通讯方式召开，应参加本次会议董事 8 人，亲自参加会议董事 8 人。本次会议的召开程序符合《公司法》和《公司章程》 的规定，会议合法有效。本次会议由公司董事长蒋国平先生主持，经审议，与会 董事以通讯表决方式通过以下决议： 股票简称：海正药业 股票代码：600267 公告编号：临 2023-85 号 债券简称：海正定转 债券代码：110813 浙江海正药业股份有限公司 第九届董事会第十七次会议决议公告 一、2023 年半年度报告及摘要； 同意 8 票，反对 0 票，弃权 0 票。 2023 年半年度报告全文及摘要详见上海证券交易所网站（www.sse.com.cn）， 2023 年半年度报告摘要同时登载于 2023 年 8 月 22 日的《中国证券报》《上海证 券报》《证券时报》。 二、关于公司变更注册资本并修订《公司章程》及办理工商变更登记的议 案； 同意 8 票 ...

浙江海正药业股份有限公司章程 浙江海正药业股份有限公司 章 程 二○二三年八月 第 1 页 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 3 | | 第三节 | 股份转让 | 4 | | 第四章 | 股东和股东大会 | 5 | | 第一节 | 股东 | 5 | | 第二节 | 股东大会的一般规定 | 7 | | 第三节 | 股东大会的召集 | 9 | | 第四节 | 股东大会的提案与通知 | 10 | | 第五节 | 股东大会的召开 | 11 | | 第六节 | 股东大会的表决和决议 | 14 | | 第五章 | 董事会 | 18 | | 第一节 | 董事 | 18 | | 第二节 | 独立董事 | 20 | | 第三节 | 董事会 | 21 | | 第四节 | 董事会秘书 | 25 | | 第六章 | 经理及其他高级管理人员 | 27 | | 第七章 | 监事会 | 28 | | 第一节 | 监事 | 28 | | 第二节 | 监 ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：2023-88 号 | | --- | --- | --- | | 债券代码：110813 | 债券简称：海正定转 | | 浙江海正药业股份有限公司关于持股 5%以上股东集 中竞价减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，浙江海正药业股份有限公司（以下简称"公司"）持 股 5%以上股东浙江省国际贸易集团有限公司（以下简称"国贸集团"）持有公司 无限售条件流通股 74,647,907 股，占当时公司总股本的 6.32%。 由于首次及预留授予激励对象 29 人不再具备股权激励资格及 1 人因个人业 绩考核要求未达标，公司于 2023 年 7 月 6 日办理完毕上述激励对象持有的全部 或部分限制性股票共计 1,639,400 股的回购注销手续；另因公司可转换公司债券 发生转股，截至本公告披露日，累计转股股数为 29,122,774 股。由于公司总股本 发生变动，国贸集团在本次减持 ...

| 股票简称：海正药业 | 股票代码：600267 公告编号：临2023-86号 | | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | 浙江海正药业股份有限公司 关于变更注册资本并修订《公司章程》的公告 1 元，减少资本公积（股本溢价）人民币12,723,070.47元。截至2023年7月6日， 公司变更后的注册资本为人民币1,207,873,677.00元，实收资本为人民币 1,207,873,677.00元。 上述可转债转股及限制性股票回购注销手续完成后，公司总股本将增加至 1,207,873,677股，公司注册资本将增加至120,787.3677万元。根据《中华人民共 和国公司法》及《公司章程》相关规定，鉴于公司注册资本和股份总数发生变 化，公司对《公司章程》部分条款进行相应修订，具体内容如下： | 修订前 | | 修订后 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 第六条 公 司 注 册 资 本 为 人 民 币 | | 第六条 | | | | 公 司 注 册 资 本 为 人 民 币 | | 118,0 ...

| 证券代码：600267 | 证券简称：海正药业 | 公告编号：临 | 2023-87 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110813 | 债券简称：海正定转 | | | | 浙江海正药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 9 月 19 日 13 点 30 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 19 日 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 ...

浙江海正药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 | 证券简称：海正药业 | 证券代码：600267 | 公告编号：2023-84 | 号 | | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 15 日（星期二）至 8 月 21 日（星期一）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过浙江海正药业股份有限 公司（以下简称"公司"）证券管理部邮箱 stock600267@hisunpharm.com 进行提 问。公司将在信息披露允许的范围内，于说明会上对投资者普遍关注的问题进行 回答。 公司将于 2023 年 8 月 22 日发布公司 2023 年半年度报告，为便于广大投资 者更全面深入地了解公司 2023 年半年度经 ...

| 证券简称：海正药业 | 证券代码：600267 | 公告编号：2023-48 | 号 | | --- | --- | --- | --- | | 债券简称：海正定转 | 债券代码：110813 | | | 浙江海正药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 12 日（星期五）至 5 月 18 日（星期四）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券管理部邮箱 stock600267@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 浙江海正药业股份有限公司（以下简称"公司"）已分别于 2023 年 3 月 31 日、4 月 25 日发布公司 2022 年年度报告、2023 年第一季度报告，为便于广大投 资者更全 ...

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 5,331,417,995.09, a decrease of 3.16% compared to CNY 5,505,183,389.05 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 14,844,990.98, an increase of 9.93% from CNY 13,504,035.96 year-on-year[19]. - The net cash flow from operating activities increased by 141.91% to CNY 435,692,337.28, compared to CNY 180,107,375.79 in the previous year[19]. - The total assets at the end of the reporting period were CNY 22,179,419,290.74, reflecting a 2.51% increase from CNY 21,636,418,678.91 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 0.51% to CNY 6,688,233,742.86 from CNY 6,722,514,670.83 at the end of the previous year[19]. - Basic earnings per share for the first half of 2018 were CNY 0.015, up 7.14% from CNY 0.014 in the same period last year[20]. - The weighted average return on net assets increased to 0.221% from 0.200% year-on-year, an increase of 0.021 percentage points[20]. - The company reported a significant decrease in the basic earnings per share after deducting non-recurring gains and losses, which was CNY -0.065 compared to CNY -0.001 in the previous year, a drop of 6,400%[20]. Business Operations - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of chemical raw materials and formulations[25]. - The company has a diversified business model, including chemical raw materials, domestic formulations, biological drugs, and pharmaceutical commercial operations[25]. - The company’s sales network covers over 4,500 hospitals across 31 provinces, municipalities, and autonomous regions in China[31]. - The company’s procurement model requires raw material suppliers to pass audits by regulatory bodies such as the FDA and EDQM[26]. - The company’s production model is based on sales forecasts, maintaining appropriate safety stock levels[29]. - The company’s pharmaceutical commercial business includes third-party sales and distribution, primarily in Zhejiang province[33]. - The company is expanding its international market presence while focusing on domestic market growth in therapeutic areas such as oncology and infectious diseases[25]. Research and Development - The company has filed a total of 827 patent applications, with 347 granted as of June 2018, indicating a strong focus on research and development[40]. - The company is advancing multiple clinical trials, including a monoclonal antibody injection for tumor necrosis factor-α, which has completed Phase III clinical trials[44]. - The company has two oral solid dosage forms that have passed the consistency evaluation for generic drugs, with one being the first in the nation to do so[46]. Financial Position and Investments - The company achieved sales revenue of 2.31 billion RMB in the first half of 2018, completing 54% of the annual sales target[48]. - Research and development expenditure rose by 29.35% to 448.69 million RMB compared to the previous year[53]. - The company completed a capital increase of 280 million RMB for its wholly-owned subsidiary, Hai Zheng Pharmaceutical Nantong Co., Ltd.[57]. - The company has invested a total of ¥436,991.20 million in various projects, with a cumulative actual investment of ¥278,546.46 million[61]. - The company is expanding its biological monoclonal antibody production project with an investment of ¥44,476.11 million, currently in the construction phase[61]. Risks and Challenges - The company is facing operational risks related to market fluctuations in its formulation products[65]. - The company's formulation business has become the main source of revenue and profit, with a significant reliance on entering the national medical insurance directory for sales growth[66]. - Over 85% of the company's raw materials are sold to international markets, facing intensified competition due to industry shifts towards lower-cost production countries like China and India[67]. - The company is highly dependent on raw material supplies, with price fluctuations in agricultural and petrochemical products significantly affecting production costs[69]. - Environmental and safety production risks are present, with potential penalties for non-compliance with national regulations impacting operational performance[70]. - Government pricing policies for drugs are leading to a continuous decline in domestic drug prices, negatively impacting operational performance[72]. - Changes in the national essential drug list or medical insurance drug list could affect the competitiveness and sales volume of the company's products[73]. Shareholder and Corporate Governance - The company did not propose any profit distribution or capital reserve transfer plan for the half-year period[79]. - There were no major litigation or arbitration matters during the reporting period[82]. - The company has not made any changes to its accounting firm during the audit period[81]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[82]. - The company has committed to not engaging in any competitive activities with its subsidiaries and affiliates[80]. - The company has not reported any significant changes in the integrity status of its controlling shareholders or actual controllers during the reporting period[82]. Environmental and Compliance - The company discharged 78.21 million tons of wastewater in the first half of 2018, with a permitted discharge limit of 88.01 million tons[90]. - The average concentration of chemical oxygen demand (COD) in wastewater was 204 mg/L, with a total discharge of 159.71 tons[90]. - The company has two wastewater treatment systems in the Taizhou area with a total capacity of 8,000 tons per day[94]. - The company is currently constructing a second wastewater treatment station in Hangzhou with a capacity of 6,000 tons per day[94]. - The company has implemented environmental monitoring plans for waste gas, wastewater, and noise according to regulatory requirements[98]. - The company is committed to sustainable development and has emphasized pollution prevention and control measures[100]. Accounting and Financial Reporting - The company has established specific accounting policies for bad debt provisions, fixed asset depreciation, and revenue recognition[168]. - The company adheres to the accounting standards, ensuring that financial statements accurately reflect its financial position and operating results[169]. - The company includes all subsidiaries under its control in the consolidated financial statements, based on the financial statements of the parent and its subsidiaries[174]. - The company recognizes impairment losses for available-for-sale debt instruments when there is objective evidence of impairment, such as significant financial difficulties of the debtor[187]. - The company uses an aging analysis method to determine the provision for bad debts, with specific percentages applied based on the aging of receivables[190].

Financial Performance - In 2017, the company's operating revenue reached ¥10,571,526,723.16, an increase of 8.61% compared to ¥9,733,423,460.10 in 2016[22] - The net profit attributable to shareholders of the listed company was ¥13,566,226.70, a significant recovery from a loss of ¥94,428,052.18 in 2016[22] - The net cash flow from operating activities increased by 59.91% to ¥1,240,708,247.39 from ¥775,899,337.79 in the previous year[22] - Total assets grew by 4.23% to ¥21,636,418,678.91 compared to ¥20,758,272,494.07 in 2016[22] - The net assets attributable to shareholders of the listed company slightly decreased by 0.48% to ¥6,722,514,670.83 from ¥6,755,159,903.78 in 2016[22] - Basic earnings per share for 2017 was CNY 0.01, compared to a loss of CNY 0.10 in 2016, marking a significant recovery[24] - The company's total revenue for Q1 2017 was CNY 2,737,986,619.26, with a slight decrease in subsequent quarters, reaching CNY 2,395,218,727.30 in Q4 2017[26] - The net profit attributable to shareholders for Q4 2017 was CNY 8,455,591.65, recovering from a loss of CNY 8,393,400.91 in Q3 2017[26] - The company reported a total operating cash flow of CNY 597,925,726.42 in Q4 2017, showing a strong cash generation capability[26] Dividend Policy - The company plans to distribute a cash dividend of ¥0.5 per 10 shares, totaling ¥48,276,592.1, while retaining the remaining undistributed profits for future growth[5] - The company did not propose a cash profit distribution plan for the reporting period despite having positive distributable profits for ordinary shareholders[174] - The company distributed cash dividends of 0.5 yuan per 10 shares in 2017, with a total cash dividend amounting to 48,276,592.10 yuan, representing 355.86% of the net profit attributable to ordinary shareholders[173] - In 2016, the company also distributed cash dividends of 0.5 yuan per 10 shares, with a total cash dividend of 48,276,592.10 yuan, while the net profit attributable to ordinary shareholders was -94,428,052.18 yuan[173] Research and Development - In 2017, the company achieved a research and development investment of 844 million yuan, accounting for 7.99% of sales revenue[56] - The company received 18 clinical approvals for 9 products during the year, including 3 approvals for biological drugs[56] - The company filed 52 patent applications in 2017, with 49 being invention patents, and held a total of 306 authorized patents by the end of the year[51] - The company expanded its clinical research team to over 100 members, including 7 PhDs, to enhance clinical trial design and monitoring[52] - The company has several ongoing major R&D projects, with a total cumulative investment of CNY 9,859.66 million in a Phase III clinical trial for a recombinant anti-tumor necrosis factor-α product[122] - The company is actively developing new products, with a total of 15 products in various stages of clinical trials, including those for diabetes and breast cancer[123] Market and Industry Trends - The global pharmaceutical market has been growing rapidly, with China's formulation sales reaching approximately 550.8 billion yuan (83 billion USD) in 2016, making it the second-largest market globally with an 8.2% market share[44] - The pharmaceutical manufacturing industry in China saw a revenue growth of 12.1% year-on-year in the first nine months of 2017, with profits increasing by 18.4% compared to the same period in 2016[45] - The pharmaceutical industry in China is expected to continue growing due to increasing healthcare awareness, an aging population, and government policy support[45] - The implementation of the two-invoice system for drug procurement is expected to significantly impact the pharmaceutical industry's sales model, with most regions set to adopt it by 2018[102] - The Chinese government aims to control the average growth of public hospital medical expenses to below 10% in 2017, with a focus on comprehensive reform of public hospitals[101] Operational Efficiency - The company is committed to ensuring the accuracy and completeness of its financial reports, as confirmed by its auditing firm, Tianjian Accounting Firm[4] - The company has established a comprehensive sales network covering over 5,000 hospitals in China, with 80% of its raw material drug revenue coming from overseas markets[47] - The company’s procurement model for raw materials requires compliance with FDA and GMP standards, ensuring high-quality production processes[36] - The company’s production model is based on sales forecasts, maintaining appropriate safety stock levels to meet market demand effectively[38] Risks and Challenges - The company has outlined potential risks in its report, emphasizing the importance of investor awareness regarding future plans and strategies[8] - The company faces risks from changes in drug pricing policies and adjustments to the national essential drug list, which could adversely affect its operating performance[166][167] - The company emphasizes the high-tech and high-risk nature of its pharmaceutical products, highlighting the uncertainties in clinical trial progress and market competition[123] Corporate Governance - The company has been actively working on improving its corporate governance structure and incentive mechanisms to enhance employee motivation[183] - The company received a warning from the Zhejiang Securities Regulatory Bureau on February 8, 2017, due to failure to timely disclose changes in the supply situation of a specific product, which was inconsistent with previous disclosures[181] - The company was selected as one of the first batch of state-controlled mixed-ownership enterprises for employee stock ownership pilot projects in Zhejiang Province on April 7, 2017[184] Investment and Financing - The company plans to issue up to 90.09 million shares at a price of 13.00 RMB per share, raising a total of no more than 1.17117 billion RMB through an employee stock ownership plan approved on October 15, 2016[183] - The company has applied for financial assistance from its controlling shareholder, with a total amount not exceeding RMB 400 million, of which RMB 300 million principal remains unpaid as of the report date[188] - The company has a cash management plan that allows for rolling use of funds within 12 months[194] - The company has a total of CNY 2.3 billion in idle raised funds available for cash management[194]